AMPH

Amphastar Pharmaceuticals, Inc. [AMPH] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AMPH Stock Summary

Top 10 Correlated ETFs

AMPH


Top 10 Correlated Stocks

AMPH


In the News

10:31 29 Mar 2024 AMPH

Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

06:56 29 Mar 2024 AMPH

Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $43.21, representing a -0.96% change from its previous close.

10:15 29 Mar 2024 AMPH

New Strong Sell Stocks for March 18th

ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.

10:31 29 Mar 2024 AMPH

Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

04:05 29 Mar 2024 AMPH

Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, 2024 at 11:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

07:46 29 Mar 2024 AMPH

Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript

06:26 29 Mar 2024 AMPH

Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.73 per share a year ago.

06:45 29 Mar 2024 AMPH

Amphastar Pharmaceuticals (AMPH) Increases Yet Falls Behind Market: What Investors Need to Know

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $51.91, denoting a +1.29% change from the preceding trading day.

10:30 29 Mar 2024 AMPH

Wall Street Bulls Look Optimistic About Amphastar (AMPH): Should You Buy?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

04:01 29 Mar 2024 AMPH

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024

RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

AMPH Financial details

Company Rating
Strong Buy
Market Cap
2.1B
Income
137.55M
Revenue
644.4M
Book val./share
12.06
Cash/share
4.89
Dividend
-
Dividend %
-
Employees
1.76K
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
20.45
Forward P/E
9.98
PEG
4
P/S
4.53
P/B
4.65
P/C
8.98
P/FCF
19.47
Quick Ratio
1.63
Current Ratio
2.1
Debt / Equity
0.93
LT Debt / Equity
0.92
-
-
EPS (TTM)
2.84
EPS next Y
4.4
EPS next Q
0.74
EPS this Y
51.6%
EPS next Y
54.8%
EPS next 5Y
124.65%
EPS last 5Y
22.34%
Revenue last 5Y
14.86%
Revenue Q/Q
-1.36%
EPS Q/Q
-25.74%
-
-
-
-
SMA20
-15.66%
SMA50
-22.78%
SMA100
-3.42%
Inst Own
57.5%
Inst Trans
0.88%
ROA
9%
ROE
24%
ROC
0.13%
Gross Margin
54%
Oper. Margin
29%
Profit Margin
22%
Payout
-
Shs Outstand
48.1M
Shs Float
34.54M
-
-
-
-
Target Price
35
52W Range
35.62-67.66
52W High
-34.46%
52W Low
+25.46%
RSI
37.74
Rel Volume
0.91
Avg Volume
497.22K
Volume
453.25K
Perf Week
-1.48%
Perf Month
-20.06%
Perf Quarter
-5.71%
Perf Half Y
-3.52%
-
-
-
-
Beta
0.848
-
-
Volatility
0.39%, 4.43%
Prev Close
0.9%
Price
43.91
Change
0.85%

AMPH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
6.467.449.169.5212.16
Net income per share
0.980.021.31.742.6
Operating cash flow per share
0.841.222.051.73.46
Free cash flow per share
00.51.481.242.74
Cash per share
1.712.252.863.354.89
Book value per share
7.648.559.3310.0812.06
Tangible book value per share
7.748.688.519.370.49
Share holders equity per share
7.648.559.3310.0812.06
Interest debt per share
1.341.442.211.9911.75
Market cap
962.71M945.93M1.11B1.47B3.28B
Enterprise value
955.65M920.56M1.09B1.42B3.76B
P/E ratio
19.67862.2917.9116.0723.83
Price to sales ratio
2.992.72.542.945.09
POCF ratio
23.0516.5211.3616.4717.86
PFCF ratio
4.65K40.4115.7722.5522.56
P/B Ratio
2.522.352.52.785.13
PTB ratio
2.522.352.52.785.13
EV to sales
2.962.632.492.845.83
Enterprise value over EBITDA
-24.5K84.0415.6113.1715.56
EV to operating cash flow
22.8816.0811.1315.8720.47
EV to free cash flow
4.62K39.3215.4721.7325.85
Earnings yield
0.0500.060.060.04
Free cash flow yield
00.020.060.040.04
Debt to equity
0.170.170.230.190.93
Debt to assets
0.110.110.160.140.39
Net debt to EBITDA
181.03-2.32-0.31-0.51.98
Current ratio
2.842.493.063.992.17
Interest coverage
-0.33-38.0448.7442.666.85
Income quality
0.952.21.550.981.33
Dividend Yield
00.020.010.010.14
Payout ratio
021.120.260.173.3
Sales general and administrative to revenue
0.160.140.120.090.08
Research and developement to revenue
0.210.190.140.150.1
Intangibles to total assets
0.070.060.060.050.41
Capex to operating cash flow
-1-0.59-0.28-0.27-0.21
Capex to revenue
-0.13-0.1-0.06-0.05-0.06
Capex to depreciation
-1.97-1.34-1.03-0.84-0.91
Stock based compensation to revenue
0.050.060.040.040.03
Graham number
12.982.1216.5219.8926.54
ROIC
0-0.010.060.10.13
Return on tangible assets
0.0900.10.130.15
Graham Net
0.310.450.341.54-8.96
Working capital
165.23M167.48M214.31M283.46M264.19M
Tangible asset value
386.38M408.11M406.65M491.36M26.13M
Net current asset value
95.8M97.17M92.11M164.99M-383.89M
Invested capital
0.170.170.230.190.93
Average receivables
48.95M56.04M72.66M83.95M101.96M
Average payables
82.23M86.28M92.52M86.89M54.84M
Average inventory
89.91M103.67M94.82M98.2M104.71M
Days sales outstanding
51.7369.2765.8165.0865.11
Days payables outstanding
147.68168.8137.31122.9330.91
Days of inventory on hand
211.79171.15142.31151.16128.58
Receivables turnover
7.065.275.555.615.61
Payables turnover
2.472.162.662.9711.81
Inventory turnover
1.722.132.562.412.84
ROE
0.1300.140.170.22
Capex per share
-0.83-0.72-0.57-0.46-0.72

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.612.692.743.353.36
Net income per share
0.660.50.490.910.68
Operating cash flow per share
0.290.781.031.190.45
Free cash flow per share
0.170.590.8610.27
Cash per share
3.43.713.075.564.89
Book value per share
10.2210.5611.111.0412.06
Tangible book value per share
9.59.84-0.68-0.450.49
Share holders equity per share
10.2210.5611.111.0412.06
Interest debt per share
1.991.979.8912.7311.37
Market cap
1.45B1.95B3.05B2.48B3.28B
Enterprise value
1.4B1.87B3.43B2.89B3.76B
P/E ratio
10.6818.7229.212.622.67
Price to sales ratio
10.7313.9220.9413.7318.41
POCF ratio
95.1748.2655.5638.55137.4
PFCF ratio
162.5363.0666.5345.8227.36
P/B Ratio
2.743.555.184.175.13
PTB ratio
2.743.555.184.175.13
EV to sales
10.3413.3923.5515.9821.1
Enterprise value over EBITDA
36.8956.0693.0239.755.45
EV to operating cash flow
91.6646.4162.4944.85157.48
EV to free cash flow
156.5260.6574.8253.3260.58
Earnings yield
0.020.010.010.020.01
Free cash flow yield
0.010.020.020.020
Debt to equity
0.190.190.91.130.93
Debt to assets
0.140.130.380.440.39
Net debt to EBITDA
-1.41-2.2310.35.587.07
Current ratio
3.993.861.532.12.17
Interest coverage
71.6565.42-10.245.35.71
Income quality
0.451.552.11.310.66
Dividend Yield
00000
Payout ratio
0.060.180.380.040
Sales general and administrative to revenue
0.080.10.080.070.07
Research and developement to revenue
0.130.140.120.090.1
Intangibles to total assets
0.050.050.450.40.41
Capex to operating cash flow
-0.41-0.23-0.16-0.16-0.4
Capex to revenue
-0.05-0.07-0.06-0.06-0.05
Capex to depreciation
-0.85-1.28-1.29-0.75-0.68
Stock based compensation to revenue
0.030.040.030.030.03
Graham number
12.2810.9111.0815.0613.61
ROIC
0.050.030.030.040.04
Return on tangible assets
0.050.040.030.050.04
Graham Net
1.571.84-9.3-9.35-8.96
Working capital
283.46M302.04M133.27M285.04M264.19M
Tangible asset value
491.36M511.4M-36.37M-24.21M26.13M
Net current asset value
164.99M182.59M-404.48M-406.49M-383.89M
Invested capital
0.190.190.91.130.93
Average receivables
88.72M95.17M103.71M113.27M117.72M
Average payables
90.02M86.56M153.21M220.13M124.08M
Average inventory
103.42M103.62M104.13M107.3M107.91M
Days sales outstanding
59.3165.1665.560.0658.08
Days payables outstanding
118.73120.87268.29277.8127.08
Days of inventory on hand
146140.95129.03137.18112.67
Receivables turnover
1.521.381.371.51.55
Payables turnover
0.760.740.340.323.32
Inventory turnover
0.620.640.70.660.8
ROE
0.060.050.040.080.06
Capex per share
-0.12-0.18-0.17-0.19-0.18

AMPH Frequently Asked Questions

What is Amphastar Pharmaceuticals, Inc. stock symbol ?

Amphastar Pharmaceuticals, Inc. is a US stock , located in Rancho cucamonga of Ca and trading under the symbol AMPH

Is Amphastar Pharmaceuticals, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $35. The lowest prediction is $35 and the highest is $35

What is AMPH stock prediction ?

What is Amphastar Pharmaceuticals, Inc. stock quote today ?

Amphastar Pharmaceuticals, Inc. stock price is $43.91 today.

Is Amphastar Pharmaceuticals, Inc. stock public?

Yes, Amphastar Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap